William R. Wilson

TL;DR: The two main approaches, namely bioreductive prodrugs and inhibitors of molecular targets upon which hypoxic cell survival depends are reviewed, and the particular challenges and opportunities these overlapping strategies present are addressed.

TL;DR: Solid tumours contain regions at very low oxygen concentrations (hypoxia), often surrounding areas of necrosis, which provides an opportunity for tumour-selective therapy, including prodrugs activated by Hypoxia, hypoxia-specific gene therapy, targeting the hypoxIA-inducible factor 1 transcription factor, and recombinant anaerobic bacteria.

TL;DR: P pH-responsive biomaterials bring forth conformational changes in these nanocarriers through various mechanisms such as protonation, charge reversal or cleavage of a chemical bond, facilitating tumour specific cell uptake or drug release, helping to design more efficient drug delivery systems.

TL;DR: PR-104 is a novel hypoxia-activated DNA cross-linking agent with marked activity against human tumor xenografts, both as monotherapy and combined with radiotherapy and chemotherapy.

TL;DR: A method is described by which the growth inhibitory effects of cytotoxic compounds on exponentially growing adherent cell lines can be quantitated, offering the advantage that any adherent cell line can be utilized without the need for tedious cell-counting procedures.